Welcome to LookChem.com Sign In|Join Free

Hubei Vanz Pharm Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
5th
years
Home>>Products>>cas 960539-70-2 99% purity daprodustat powder

Product Certification&
Enterprise Certification

More Detail

Hubei Vanz Pharm Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Ms.Chelsea gao

Tel: 86-27-84492310

Ms.Bella Li

Tel: 008618986076206

Ms.Chelsea Gao

Tel: +86 27 84492310

Ms.Wendy

Tel: WhatsApp +8615927784577

Ms.Mirriam

Tel: +8618071739296

Mobile:

Tel: 86-27-84492310

Fax: 86-27-84402310

URL: http://www.vanzpharm.com/en/index.html

Province/state: Hubei

City: JIAYU

Street: FANHU INDUSTRY PARK

MaxCard:


    x
  • Ms.Bella Li
  • Ms.Chelsea Gao
Contact Suppliers

cas 960539-70-2 99% purity daprodustat powder

CAS NO.960539-70-2

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,MoneyGram
Contact Supplier

Product Details

Keywords

  • daprodustat
  • daprodustat powder
  • 99% daprodustat

Quick Details

  • ProName: cas 960539-70-2 99% purity daprodusta...
  • CasNo: 960539-70-2
  • Molecular Formula: C19H27N3O6
  • Appearance: white
  • Application: Artemisia annua is used as antimalaria...
  • DeliveryTime: 7-10 days
  • PackAge: drum
  • Port: Shanghai/Wuhan
  • ProductionCapacity: 1000 Kilogram/Month
  • Purity: 99
  • Storage: room
  • LimitNum: 1 Kilogram

Superiority

cas  960539-70-2 99% purity daprodustat powder 

Product Name:    daprodustat,GSK1278863
CAS:    960539-70-2
MF:    C19H27N3O6
MW:    393.43
EINECS:    691-659-9

 

Details

cas  960539-70-2 99% purity daprodustat powder 

Product Name:    daprodustat 
CAS:    960539-70-2
MF:    C19H27N3O6
MW:    393.43
EINECS:    691-659-9 

Daprodustat is a novel HIF (Hypoxia inducible factor)-prolyl hydroxylase inhibitor.
daprodustat (gsk1278863) is a hif-prolyl hydroxylase inhibitor.hypoxia stimulates erythropoietin (epo) release through accumulation of hypoxia-inducible factor 1α (hif-1α), resulting in an increase of erythrocyte production by the bone marrow. hif-prolyl hydroxylase inhibitors have been used to selectively activate the phd-signaling pathway, leading to the stabilization of hifα subunits, which can affect the transcription of hif-responsive genes.